过度表达的MicroRNA-455-3p在晚期发作的阿尔茨海默病中增强了认知功能
Md Ariful Islam1, Sudhir Kshirsagar1, Rainier Vladlen Alvir1
1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Brain research
|July 23, 2025
概括
微RNA-455-3p (miR-455-3p) 增强了认知和运动功能. 它的过度表达提供神经保护,而它的缺失使老鼠的阿尔茨海默病 (AD) 症状恶化.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 微RNAs (miRNAs) 是像阿尔茨海默氏症 (AD) 这样的神经退行性疾病的关键调节者.
- 与AD相关的认知和运动功能的miR-455-3p的特定作用以前未被探索.
研究的目的:
- 调查miR-455-3p过度表达和淘汰对人类化粉样β (hAbKI) 鼠标模型中的认知和运动行为的影响.
主要方法:
- 通过与hAbKI小鼠交叉miR-455-3p转基因 (TG) 和淘汰赛 (KO) 小鼠生成双重突变小鼠.
- 通过6个实验组的莫里斯水迷宫,Y迷宫,开放场地和旋转杆测试来评估认知和运动功能.
主要成果:
- miR-455-3p过度表达显著改善了运动活动,工作记忆,空间学习和运动协调.
- miR-455-3p淘汰赛影响了认知和运动性能,增加了类似焦虑的行为.
- hAbKI x miR-455-3p KO组显示了最严重的缺陷,表明miR-455-3p损失加剧了AD相关的损伤.
结论:
- miR-455-3p在调节认知和运动功能的过程中起着至关重要的作用.
- 过度表达miR-455-3p表明神经保护的好处.
- 向miR-455-3p是一个潜在的治疗策略,可以改善阿尔茨海默病和相关疾病的结果.
更多相关视频
09:06Stereotactic Injection of MicroRNA-expressing Lentiviruses to the Mouse Hippocampus CA1 Region and Assessment of the Behavioral Outcome
Published on: June 10, 2013
23.1K
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
518
相关概念视频
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
209
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
209